Quick Answer
BIODESIX INC reported Stockholders Equity of -$2.47 million for the year ending 2025.
- BIODESIX INC showed a decrease of -111.8% in Stockholders Equity from 2024 to 2025.
- This data is from BIODESIX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$205.71 million | Q2 2019: -$212.52 million | Q3 2019: -$222.06 million | Q1 2020: -$234.83 million | Q2 2020: -$243.05 million | Q3 2020: -$251.78 million | Q1 2021: $36.43 million | Q2 2021: $25.77 million | Q3 2021: $16.03 million | Q1 2022: $7.78 million | Q2 2022: $7.67 million | Q3 2022: -$2.90 million | Q1 2023: $4.55 million | Q2 2023: -$6.99 million | Q3 2023: -$1.45 million | Q1 2024: -$5.50 million | Q2 2024: $36.26 million | Q3 2024: $27.86 million | Q1 2025: $11.06 million | Q2 2025: $1.14 million | Q3 2025: -$1.72 million.
- Over the full 8 years of available data (2018 to 2025), BIODESIX INC's Stockholders Equity has grown by 98.7%.
- Historical annual values: Fiscal year 2025: -$2.47 million | Fiscal year 2024: $20.88 million | Fiscal year 2023: $4.58 million | Fiscal year 2022: $20.61 million | Fiscal year 2021: $19.73 million | Fiscal year 2020: $41.17 million | Fiscal year 2019: -$225.14 million | Fiscal year 2018: -$194.63 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: